Polyneuropathy developing after infliximab therapy in a patient with recalcitrant pyoderma gangrenosum.
The use of tumor necrosis factor-alpha (TNF-α) inhibitors has increased tremendously during the recent years. Neurological side effects associated with TNF-α inhibitors are rarely encountered, but these side effects may result in serious clinical problems. Treatment with TNF-α inhibitors is associat...
| Publicado en: | Turkish Archives of Dermatology & Venerology / Turkderm Vol. 53; no. 1; pp. 24 - 28 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | case study pictorial Journal Article |
| Publicado: |
Galenos Yayinevi Tic. LTD. STI
2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | The use of tumor necrosis factor-alpha (TNF-α) inhibitors has increased tremendously during the recent years. Neurological side effects associated with TNF-α inhibitors are rarely encountered, but these side effects may result in serious clinical problems. Treatment with TNF-α inhibitors is associated with demyelinating syndromes which can affect both the central and peripheral nervous systems. Short-term follow-up indicates relatively good outcomes, sometimes after just treatment discontinuation, although corticosteroids or intravenous immunoglobulin may be necessary to reverse the conditions in some cases. Here, we present a case of motor neuropathy developing after treatment with infliximab in a patient with recalcitrant pyoderma gangrenosum. Tümör nekroz faktörü-alfa (TNF-α) inhibitörlerinin birçok romatizmal ve otoimmün hastalığın tedavisinde kullanımları son yıllarda artmıştır. TNF-α inhibitörlerine bağlı nörolojik yan etkiler nadir görülmelerine karşın oldukça ciddi komplikasyonlar oluşturabilirler. TNF-α inhibitörleri hem santral hem de periferik sinir sistemine ilişkin demiyelinizan tablolara yol açabilir. Klinik tablo, biyolojik ajan tedavisinin kesilmesi ile düzelebildiği gibi, bazı olgularda sistemik steroid veya intravenöz immünoglobülin tedavisine gereksinim duyulabilir. Burada, standart tedaviye dirençli piyoderma gangrenosum nedeniyle infliksimab tedavisi başlanmasından sonra motor nöropati gelişen bir olgu sunulmaktadır. |
|---|